Cholesteryl hyaluronic acid-coated, reduced graphene oxide nanosheets for anti-cancer drug delivery

Biomaterials

Volumn 34, Issue 37, 2013, Pages 9638-9647

  Miao, Wenjun ^a   Shim, Gayong ^a   Kang, Choong Mo ^b   Lee, Soondong ^a   Choe, Yearn Seong ^b   Choi, Han Gon ^c   Oh, Yu Kyoung ^a  

^a Seoul National University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

Anti tumor effect; Doxorubicin; Graphene based nanosheets; Hyaluronic acid

Indexed keywords

ANTI-CANCER DRUG DELIVERY; ANTI-TUMOR EFFICACY; ANTITUMOR EFFECT; DOXORUBICIN; INTRAVENOUS ADMINISTRATION; PHYSIOLOGICAL CONDITION; REDUCED GRAPHENE OXIDES; REDUCED GRAPHENE OXIDES (RGO);

DRUG DELIVERY; GRAPHENE; HYALURONIC ACID; MAMMALS; NANOSHEETS; ORGANIC ACIDS; TUMORS;

LOADING;

CHOLESTERYL HYALURONIC ACID; DOXORUBICIN; GRAPHENE OXIDE; HERMES ANTIGEN; HYALURONIC ACID DERIVATIVE; NANOCARRIER; NANOCOATING; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING COMPETITION; CANCER SURVIVAL; CELL STRAIN KB; CHEMICAL MODIFICATION; COLLOID; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; GENE OVEREXPRESSION; IN VIVO STUDY; MOLECULAR STABILITY; MOUSE; NANOFABRICATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SURVIVAL RATE; TUMOR VOLUME;

MUS;

ANTI-TUMOR EFFECT; DOXORUBICIN; GRAPHENE-BASED NANOSHEETS; HYALURONIC ACID;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; GRAPHITE; HUMANS; HYALURONIC ACID; KB CELLS; MICE; NANOSTRUCTURES; NEOPLASMS; OXIDATION-REDUCTION; OXIDES;

EID: 84884815625     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.08.058     Document Type: Article

References (34)

1. Park S., Ruoff R.S. Chemical methods for the production of graphenes. Nat Nanotech 2009, 4:217-224.
2. Dreyer D.R., Park S., Bielawski C.W., Ruoff R.S. The chemistry of graphene oxide. Chem Soc Rev 2010, 39:228-240.
3. Loh K.P., Bao Q., Ang P.K., Yang J. The chemistry of graphene. JMater Chem 2010, 20:2277-2289.
4. Wang Y., Li Z., Wang J., Li J., Lin Y. Graphene and graphene oxide: biofunctionalization and applications in biotechnology. Trends Biotechnol 2011, 29:205-212.
5. Yang K., Feng L., Shi X., Liu Z. Nano-graphene in biomedicine: theranostic applications. Chem Soc Rev 2013, 42:530-547.
6. Peng C., Hu W., Zhou Y., Fan C., Huang Q. Intracellular imaging with a graphene-based fluorescent probe. Small 2010, 6:1686-1692.
7. Sun X., Liu Z., Welsher K., Robinson J.T., Goodwin A., Zaric S., et al. Nano-graphene oxide for cellular imaging and drug delivery. Nano Res 2008, 1:203-212.
8. Miao W., Shim G., Lee S., Choe Y.S., Oh Y.K. Safety and tumor tissue accumulation of pegylated graphene oxide nanosheets for co-delivery of anticancer drug and photosensitizer. Biomaterials 2013, 34:3402-3410.
9. Liu Z., Robinson J.T., Sun X., Dai H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. JAm Chem Soc 2008, 130:10876-10877.
10. Kim Y.K., Kim M.H., Min D.H. Biocompatible reduced graphene oxide prepared by using dextran as a multifunctional reducing agent. Chem Commun 2011, 47:3195-3197.
11. Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat Rev Cancer 2011, 11:254-267.
12. Ghosh S.C., Neslihan Alpay S., Klostergaard J. CD44: a validated target for improved delivery of cancer therapeutics. Expert Opin Ther Targets 2012, 16:635-650.
13. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004, 4:528-539.
14. Avigdor A., Goichberg P., Shivtiel S., Dar A., Peled A., Samira S., et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 2004, 103:2981-2989.
15. Choi K.Y., Chung H., Min K.H., Yoon H.Y., Kim K., Park J.H., et al. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 2010, 31:106-114.
16. Yoon H.Y., Koo H., Choi K.Y., Chan Kwon I., Choi K., Park J.H., et al. Photo-crosslinked hyaluronic acid nanoparticles with improved stability for invivo tumor-targeted drug delivery. Biomaterials 2013, 34:5273-5280.
17. Nakai T., Hirakura T., Sakurai Y., Shimoboji T., Ishigai M., Akiyoshi K. Injectable hydrogel for sustained protein release by salt-induced association of hyaluronic acid nanogel. Macromol Biosci 2012, 12:475-483.
18. Oh E.J., Kim J.W., Kong J.H., Ryu S.H., Hahn S.K. Signal transduction of hyaluronic acid-peptide conjugate for formyl peptide receptor like 1 receptor. Bioconjugate Chem 2008, 19:2401-2408.
19. Li D., Muller M.B., Gilje S., Kaner R.B., Wallace G.G. Processable aqueous dispersions of graphene nanosheets. Nat Nanotech 2008, 3:101-105.
20. Lu C.H., Yang H.H., Zhu C.L., Chen X., Chen G.N. Agraphene platform for sensing biomolecules. Angew Chem Int Edit 2009, 48:4785-4787.
21. Ciani A.J., Gupta B.C., Batra I.P. Interaction of cholesterol with carbon nanotubes: a density functional theory study. Solid State Commun 2008, 147:146-151.
22. Chhikara B.S., Misra S.K., Bhattacharya S. CNT loading into cationic cholesterol suspensions show improved DNA binding and serum stability and ability to internalize into cancer cells. Nanotechnology 2012, 23:065101.
23. Swierczewska M., Choi K.Y., Mertz E.L., Huang X., Zhang F., Zhu L., et al. Afacile, one-step nanocarbon functionalization for biomedical applications. Nano Lett 2012, 12:3613-3620.
24. Ferguson E.L., Roberts J.L., Moseley R., Griffiths P.C., Thomas D.W. Evaluation of the physical and biological properties of hyaluronan and hyaluronan fragments. Int J Pharm 2011, 420:84-92.
25. Collins M.N., Birkinshaw C. Hyaluronic acid based scaffolds for tissue engineering-a review. Carbohydr Polym 2013, 92:1262-1279.
26. Wang Y.W., Wu Q., Chen G.Q. Reduced mouse fibroblast cell growth by increased hydrophilicity of microbial polyhydroxyalkanoates via hyaluronan coating. Biomaterials 2003, 24:4621-4629.
27. Chang N.J., Jhung Y.R., Yao C.K., Yeh M.L. Hydrophilic gelatin and hyaluronic acid-treated PLGA scaffolds for cartilage tissue engineering. JAppl Biomater Funct Mater 2013, 11:e45-e52.
28. Ganesh S., Iyer A.K., Morrissey D.V., Amiji M.M. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 2013, 34:3489-3502.
29. Zhang X., Yin J., Peng C., Hu W., Zhu Z., Li W., et al. Distribution and biocompatibility studies of graphene oxide in mice after intravenous administration. Carbon 2011, 49:986-995.
30. Li F., Park S.-J., Ling D., Park W., Han J.Y., Na K., et al. Hyaluronic acid-conjugated graphene oxide/photosensitizer nanohybrids for cancer targeted photodynamic therapy. JMat Chem B 2013, 1:1678-1686.
31. Kim D.J., Sohn I.Y., Jung J.H., Yoon O.J., Lee N.E., Park J.S. Reduced graphene oxide field-effect transistor for label-free femtomolar protein detection. Biosens Bioelectron 2013, 41:621-626.
32. Lobo D.E., Fu J., Gengenbach T., Majumder M. Localized deoxygenation and direct patterning of graphene oxide films by focused ion beams. Langmuir 2012, 28:14815-14821.
33. Mihara S., Tsubota T., Murakami N., Ohno T. Improvement of electrical conductivity while maintaining a high-transmittance of graphene oxide/MWCNT film by hydrazine reduction. JNanosci Nanotechnol 2012, 12:6930-6934.
34. Robinson J.T., Tabakman S.M., Liang Y., Wang H., Casalongue H.S., Vinh D., et al. Ultrasmall reduced graphene oxide with high near-infrared absorbance for photothermal therapy. JAm Chem Soc 2011, 133:6825-6831.